Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Paul J. Bröckelmann, Helen Goergen, Ulrich Keller, +18

JAMA Oncology

Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma

Jasmin Mettler, Horst Müller, Conrad‐Amadeus Voltin, +9

Journal of Nuclear Medicine

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

Conrad‐Amadeus Voltin, Helen Goergen, Christian Baues, +11

Annals of Oncology

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma

Carsten Kobe, Helen Goergen, Christian Baues, +9

Blood

Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial

Conrad‐Amadeus Voltin, Jasmin Mettler, Lutz van Heek, +14

Clinical Cancer Research

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

Lutz van Heek, Colin Stuka, Helen Kaul, +10

BMC Cancer

Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma

Conrad‐Amadeus Voltin, Jasmin Mettler, Ronald Boellaard, +5

Nuclear Medicine Communications

Prognostic value of baseline metabolic tumor volume (<scp>MTV</scp>) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase <scp>III HD17</scp> trial

Lutz van Heek, Jasmin Weindler, Claudia Gorniak, +11

European Journal Of Haematology